Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
56 studies found for:    "Dermatofibroma"
Show Display Options
Rank Status Study
21 Recruiting Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Synovial Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Stage IB Adult Soft Tissue Sarcoma;   Stage IIB Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: pazopanib hydrochloride;   Drug: ifosfamide;   Drug: doxorubicin hydrochloride;   Radiation: radiation therapy;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
22 Recruiting Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Hemangioendothelioma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Hemangiopericytoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: gemcitabine hydrochloride;   Drug: pazopanib hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis
23 Active, not recruiting Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Conditions: Sarcoma;   Leiomyosarcoma;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Fibrous;   Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Intervention: Drug: Gemcitabine and Docetaxel in Combination with Pazopanib
24 Active, not recruiting Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma of Bone;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Hemangiopericytoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Mixed Childhood Rhabdomyosarcoma;   Pleomorphic Childhood Rhabdomyosarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: cixutumumab;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
25 Active, not recruiting Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Conditions: Sarcoma;   Leiomyosarcoma;   Malignant Fibrous;   Histiocytoma;   Angiosarcoma
Intervention: Drug: gemcitabine and docetaxel with bevacizumab
26 Recruiting To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Conditions: Neuroblastoma;;   Rhabdomyosarcoma;;   Ewing's Sarcoma;;   Ewing's Tumor;;   Sarcoma, Ewing's;;   Sarcomas, Epitheliod;;   Sarcoma, Soft Tissue;;   Sarcoma, Spindle Cell;;   Melanoma;;   Malignant Melanoma;;   Clinical Oncology;;   Oncology, Medical;;   Pediatrics, Osteosarcoma;;   Osteogenic Sarcoma;;   Osteosarcoma Tumor;;   Sarcoma, Osteogenic;;   Tumors;;   Cancer;;   Neoplasia;;   Neoplasm;;   Histiocytoma;;   Fibrosarcoma;;   Dermatofibrosarcoma
Intervention: Drug: nab-paclitaxel
27 Recruiting International Rare Histiocytic Disorders Registry (IRHDR)
Conditions: Rare Histiocytic Disorders (RHDs);   Juvenile Xanthogranuloma (JXG);   Reticulohistiocytoma (Epithelioid Histiocytoma);   Xanthoma Disseminatum (XD);   Multicentric Reticulohistiocytosis (MRH);   Systemic Juvenile Xanthogranuloma;   Erdheim-Chester Disease (ECD);   Multi-system Rosai-Dorfman Disease (RDD)
Intervention: Other: Registry study
28 Recruiting Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma
Conditions: Sarcoma;   Neoplasms, Connective and Soft Tissue
Intervention: Biological: Autologous dendritic cell vaccine
29 Completed Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Condition: Tumor
Interventions: Drug: belinostat;   Drug: 5-Fluorouracil (5-FU)
30 Unknown  External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Condition: Cancer
Interventions: Drug: indinavir sulfate;   Drug: ritonavir;   Radiation: radiation therapy
31 Completed Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Condition: Sarcoma
Intervention: Drug: temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
32 Completed PET Scan Combined With CT Scan in Predicting Response in Patients Undergoing Chemotherapy and Surgery for Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Biological: pegfilgrastim;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Drug: pegylated liposomal doxorubicin hydrochloride;   Procedure: conventional surgery;   Radiation: fludeoxyglucose F 18
33 Completed Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Procedure: conventional surgery;   Procedure: hyperthermia treatment;   Radiation: radiation therapy
34 Completed Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Drug: soblidotin
35 Completed Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
Condition: Sarcoma
Interventions: Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
36 Terminated Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: trabectedin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
37 Completed Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Drug: exatecan mesylate
38 Completed Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: ifosfamide
39 Completed Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
Condition: Sarcoma
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery
40 Terminated
Has Results
Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Radiation: intensity-modulated radiation therapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-56) Show next page of results    Last Page
Indicates status has not been verified in more than two years